DEF 14A: Relmada Therapeutics Pivots Strategy After Trial Setback, Focuses on New Acquisitions and Pipeline Diversification

Relmada Therapeutics is shifting its focus to acquiring and advancing new therapeutic candidates after a Phase 3 trial for esmethadone (REL-1017) showed it was unlikely to meet its primary endpoint.

Summary

• Relmada Therapeutics is pivoting its development programs following a strategic review prompted by disappointing interim analysis results from a Phase 3 study of esmethadone (REL-1017) for Major Depressive Disorder (MDD).
• The company has paused further work on REL-1017 and is focusing on acquiring and advancing new therapeutic candidates to diversify its pipeline and balance risk.
• Relmada has in-licensed NDV-01, a novel delivery formulation of a chemotherapy regimen for non-muscle-invasive bladder cancer (NMIBC), and acquired Sepranolone, a Phase 2b-ready neurosteroid with potential applications in Prader-Willi Syndrome (PWS), essential tremor, Tourette Syndrome (TS), and other disorders.
• The company has also paused further development of REL-P11, a modified-release formulation of psilocybin for metabolic diseases, to prioritize assets with greater near-term potential.
• Key upcoming milestones include NDV-01 Phase 2a data presentation in April 2025, NDV-01 IND clearance in the second half of 2025, and Sepranolone clinical program initiation in PWS by year-end 2025.
• The Board of Directors is seeking shareholder approval to amend the 2021 Equity Incentive Plan to increase the shares of common stock available for issuance thereunder by 2.0 million shares.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the failure of the Phase 3 trial is a significant setback, the company's proactive response and pipeline diversification efforts are viewed positively. The overall sentiment is cautiously optimistic.

Positives

• Relmada has diversified its pipeline with the in-licensing of NDV-01 and the acquisition of Sepranolone, mitigating risk and enhancing growth potential.
• The company is prioritizing midto late-stage programs with a clear path to commercialization.
• NDV-01 offers a controlled-release chemotherapy solution for NMIBC with the potential to improve treatment outcomes amid the ongoing BCG shortage.
• Sepranolone has shown potential to improve TS symptoms, achieving a 28% reduction in tic severity in a Phase 2a study.
• The company has an experienced management team with considerable drug development expertise.

Negatives

• The Phase 3 study of esmethadone (REL-1017) for MDD was unlikely to meet its primary efficacy endpoint with statistical significance, leading to a pause in further work on the program.
• The company has paused further development of REL-P11, a modified-release formulation of psilocybin for metabolic diseases.

Risks

• The company's strategic shift involves risks associated with acquiring and developing new therapeutic candidates.
• The success of NDV-01 and Sepranolone is subject to clinical trial outcomes, regulatory approvals, and market acceptance.
• The company faces competition in the pharmaceutical industry.
• The company's stock price is subject to a variety of factors outside of its control.

Future Outlook

Relmada Therapeutics anticipates achieving multiple key milestones over the next 12 months, including NDV-01 Phase 2a data presentation, NDV-01 IND clearance, and Sepranolone clinical program initiation in PWS. The company is poised for meaningful progress in 2025 and beyond with a strengthened development pipeline and disciplined execution.

Management Comments

• Following a comprehensive strategic review, we have taken decisive actions to pivot our development programs in response to the interim analysis results of our Phase 3 study of esmethadone (REL -1017 ) for Major Depressive Disorder (MDD).
• In response to this development, we have determined that the most strategic path forward is to leverage our extensive drug development expertise to acquire and advance new therapeutic candidates.
• We are confident that this refined strategic direction strengthens our ability to deliver shareholder value while maintaining our commitment to scientific innovation and positive patient impact.

Industry Context

The company's pivot comes amid increasing competition in the pharmaceutical industry and a growing focus on pipeline diversification to mitigate risk. The BCG shortage mentioned in the document highlights a specific market opportunity for NDV-01 in the treatment of NMIBC.

Comparison to Industry Standards

• Relmada's strategic shift to acquire Phase 2b-ready assets like Sepranolone mirrors a trend among biotech companies to de-risk their pipelines and accelerate time to market.
• The company's focus on targeted commercialization strategies aligns with industry best practices for companies with limited sales and marketing infrastructure.
• The company's decision to pause the REL-P11 program reflects a cautious approach to the evolving regulatory landscape for psychedelics, similar to other companies in the space.

Management Changes

Related Party Transactions

• The document references a License Agreement regarding our Intellectual Property Assignment Agreement and License Agreement with Dr. Charles E. Inturrisi and Dr. Paolo Manfredi, as it relates to our Chief Executive Officer, Sergio Traversa.
• The document references a Psilocybin License Agreement In July 2021, we executed a License Agreement with Arbormentis, LLC which gives us the development and commercial rights to a novel psilocybin and derivate program. Dr. Paolo Manfredi, our Acting Chief Scientific Officer and co -inventor of REL -1017 , and Dr. Marco Pappagallo, Safety/Adjudication Officer, are among the scientists affiliated with Arbormentis, LLC.

Stakeholder Impact

• Shareholders: The strategic shift aims to deliver shareholder value through pipeline diversification and new acquisitions.
• Employees: The company's ability to attract and retain qualified personnel is crucial for its success.
• Patients: The development of new therapies like NDV-01 and Sepranolone has the potential to improve treatment outcomes for patients with NMIBC, PWS, essential tremor, and Tourette Syndrome.

Next Steps

• NDV-01 Phase 2a data presentation at the 2025 American Urological Association Meeting.
• NDV-01 Investigational New Drug (IND) clearance in the United States.
• Sepranolone clinical program initiation in PWS.

Key Dates

Keywords

Relmada Therapeutics, Sepranolone, NDV-01, Esmethadone, REL-1017, NMIBC, PWS, Tourette Syndrome, Clinical Trials, Acquisition, In-Licensing, Pipeline Diversification, Equity Incentive Plan